<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3793945</article-id><article-id pub-id-type="pmid">24130794</article-id><article-id pub-id-type="publisher-id">PONE-D-13-18266</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0076820</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>The Novel PPAR α/γ Dual Agonist MHY 966 Modulates UVB–Induced Skin Inflammation by Inhibiting NF-κB Activity </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">MHY 966 Suppresses the NF-κB Pathway</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Park</surname><given-names>Min Hi</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Ji Young</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Hye Jin</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Dae Hyun</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chung</surname><given-names>Ki Wung</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Daeui</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jeong</surname><given-names>Hyoung Oh</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Hye Rim</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Chan Hum</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>So Ra</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chun</surname><given-names>Pusoon</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Byun</surname><given-names>Youngjoo</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Moon</surname><given-names>Hyung Ryong</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chung</surname><given-names>Hae Young</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Molecular Inflammation Research Center for Aging Intervention (MRCA), College of Pharmacy, Pusan National University, Busan, Korea</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Laboratory of Biochemistry, Pusan National University, Busan, Korea</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Laboratory of Medicinal Chemistry, College of Pharmacy, Pusan National University, Busan, Korea</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>College of Pharmacy, Inje University, Gimhae, Gyeongnam, Korea</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>College of Pharmacy, Korea University, Chungnam, Korea</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Bassaganya-Riera</surname><given-names>Josep</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Virginia Tech, United States of America</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>mhr108@pusan.ac.kr</email> (HRM); <email>hyjung@pusan.ac.kr</email> (HYC)</corresp><fn fn-type="COI-statement"><p><text><SENT sid="1" pm="."><plain>Competing Interests: The authors have declared that no competing interests exist. </plain></SENT>
</text></p></fn><fn fn-type="con"><p><text><SENT sid="2" pm="."><plain>Conceived and designed the experiments: MHP DHK HRM HYC. </plain></SENT>
<SENT sid="3" pm="."><plain>Performed the experiments: MHP DP HOJ KWC CHP SRK. </plain></SENT>
<SENT sid="4" pm="."><plain>Analyzed the data: MHP DHK HRM HYC. </plain></SENT>
<SENT sid="5" pm="."><plain>Contributed reagents/materials/analysis tools: JYP HJL HRK PC YB. </plain></SENT>
<SENT sid="6" pm="."><plain>Wrote the manuscript: MHP HRM HYC. </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>9</day><month>10</month><year>2013</year></pub-date><volume>8</volume><issue>10</issue><elocation-id>e76820</elocation-id><history><date date-type="received"><day>27</day><month>4</month><year>2013</year></date><date date-type="accepted"><day>29</day><month>8</month><year>2013</year></date></history><permissions><copyright-statement>© 2013 Park et al</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Park et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="7" pm="."><plain>Ultraviolet B (UVB; 290~320nm) irradiation-induced lipid peroxidation induces inflammatory responses that lead to skin wrinkle formation and epidermal thickening. </plain></SENT>
<SENT sid="8" pm="."><plain>Peroxisome proliferator-activated receptor (PPAR) α/γ dual agonists have the potential to be used as anti-wrinkle agents because they inhibit inflammatory response and lipid peroxidation. </plain></SENT>
<SENT sid="9" pm="."><plain>In this study, we evaluated the function of 2-bromo-4-(5-chloro-benzo[d]thiazol-2-yl) phenol (MHY 966), a novel synthetic PPAR α/γ dual agonist, and investigated its anti-inflammatory and anti-lipid peroxidation effects. </plain></SENT>
<SENT sid="10" pm="."><plain>The action of MHY 966 as a PPAR α/γ dual agonist was also determined in vitro by reporter gene assay. </plain></SENT>
<SENT sid="11" pm="."><plain>Additionally, 8-week-old melanin-possessing hairless mice 2 (HRM2) were exposed to 150 mJ/cm2 UVB every other day for 17 days and MHY 966 was simultaneously pre-treated every day for 17 days to investigate the molecular mechanisms involved. </plain></SENT>
<SENT sid="12" pm="."><plain>MHY 966 was found to stimulate the transcriptional activities of both PPAR α and γ. In HRM2 mice, we found that the skins of mice exposed to UVB showed significantly increased pro-inflammatory mediator levels (NF-κB, iNOS, and COX-2) and increased lipid peroxidation, whereas MHY 966 co-treatment down-regulated these effects of UVB by activating PPAR α and γ. Thus, the present study shows that MHY 966 exhibits beneficial effects on inflammatory responses and lipid peroxidation by simultaneously activating PPAR α and γ. The major finding of this study is that MHY 966 demonstrates potential as an agent against wrinkle formation associated with chronic UVB exposure. </plain></SENT>
</text></SecTag></p></abstract><funding-group><funding-statement>This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST, no. 2009-0083538). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group></article-meta></front><body><SecTag type="INTRO"><sec sec-type="introduction" id="s1"><title><text><SENT sid="16" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="17" pm="."><plain>Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear receptor superfamily, a family of ligand-activated transcriptional factors. </plain></SENT>
<SENT sid="18" pm="."><plain>PPARs function as ligand-dependent transcription factors and can heterodimerize with retinoid X receptors and then bind to PPAR-responsive elements (PPRE) in target gene promoters, which usually leads to transcriptional activation. </plain></SENT>
<SENT sid="19" pm="."><plain>Another function of PPARs is the inhibition of inflammatory gene expression. </plain></SENT>
<SENT sid="20" pm="."><plain>In several model systems, PPARs repressed the target genes of nuclear factor-κB (NF-κB). </plain></SENT>
<SENT sid="21" pm="."><plain>Another function of PPARs is the inhibition of inflammatory reaction [1]. </plain></SENT>
<SENT sid="22" pm="."><plain>For example, tesaglitazar, a well known PPAR α/γ dual agonist, has been reported to reduce pro-inflammatory cytokine levels [2] although its effects on wrinkle formation are unknown. </plain></SENT>
</text></p><p><text><SENT sid="23" pm="."><plain>The major function of the epidermis is to provide a defense against physical environmental pollutants and UVB [3]. </plain></SENT>
<SENT sid="24" pm="."><plain>These environmental toxicants are inherent oxidants and/or directly or indirectly drive the production of a variety of reactive oxidants also known as reactive oxygen species (ROS), such as, superoxide, hydrogen peroxide, and the hydroxyl radical [4]. </plain></SENT>
<SENT sid="25" pm="."><plain>ROS have an established role in UV-induced skin aging, which is characterized by wrinkle formation. </plain></SENT>
<SENT sid="26" pm="."><plain>In general, wrinkles are created by alterations in the dermal matrix, whereby collagen levels are reduced by accelerated breakdown and collagen synthesis is reduced [5]. </plain></SENT>
</text></p><p><text><SENT sid="27" pm="."><plain>UVB irradiation can have direct and indirect adverse biologic effects, which include the induction of oxidative stress, DNA damage, and premature skin aging [6]. </plain></SENT>
<SENT sid="28" pm="."><plain>Furthermore, UVB-induced ROS enhance inflammatory response by activating NF-κB [7]. </plain></SENT>
<SENT sid="29" pm="."><plain>In addition, UVB enhances the levels of NF-κB responsive proteins, such as, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), and induces the production of nitric oxide (NO), which plays a central role in regulation of skin cell apoptosis [8–10]. </plain></SENT>
<SENT sid="30" pm="."><plain>NO is produced from L-arginine and oxygen in a reaction catalyzed by iNOS and causes lipid peroxidation when it is transformed into cytotoxic peroxynitrite (ONOO-) by reacting with ROS [11,12]. </plain></SENT>
<SENT sid="31" pm="."><plain>Thus, the damage of skin tissues by lipid peroxidants is responsible for the wrinkle formation that is indicative of photoaging [4]. </plain></SENT>
</text></p><p><text><SENT sid="32" pm="."><plain>In the previous study, we reported that MHY 966 suppresses melanogenesis by inhibiting the generation of NO [13]. </plain></SENT>
<SENT sid="33" pm="."><plain>This study was undertaken to identify a novel PPAR α/γ dual agonist and to explore the hypothesis that MHY 966 prevents UVB-induced collagen degrdation by inhibiting inflammatory response. </plain></SENT>
<SENT sid="34" pm="."><plain>In the present study, we identified a novel PPAR α/γ dual agonist MHY 966, by using a reporter gene assay and by docking simulation. </plain></SENT>
<SENT sid="35" pm="."><plain>Furthermore, the anti-inflammatory effects of MHY 966 were explored in UVB-induced HRM2 mice. </plain></SENT>
<SENT sid="36" pm="."><plain>Based on these results, it appears that MHY 966 activates both PPAR α and γ, and alleviates inflammatory response, making it a potentially new treatment for UVB-induced skin inflammation. </plain></SENT>
</text></p></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="s2"><title><text><SENT sid="37" pm="."><plain>Results </plain></SENT>
</text></title><sec id="s2.1"><title><text><SENT sid="38" pm="."><plain>MHY 966 increased the transcriptional activities of PPAR α and γ </plain></SENT>
</text></title><p><text><SENT sid="39" pm="."><plain>For specific interactions between nuclear hormone receptors and their ligands, one of the key chemical bonds is the hydrogen bond, which often links ligands and amino acid residues in the ligand domain of nuclear hormone receptors. </plain></SENT>
<SENT sid="40" pm="."><plain>To identify a novel PPAR α/γ dual agonist, we used the Autodock 4.2 program. </plain></SENT>
<SENT sid="41" pm="."><plain>According to Autodock 4.2, MHY 966 linked with a 2-bromo phenol to provide numerous hydrophobic interactions in the binding pocket as well as same binding pocket with fenofibrate and rosiglitazone, known as PPAR α and γ positive control, respectively (Figure 1 A and B). </plain></SENT>
<SENT sid="42" pm="."><plain>The binding energies of MHY 966 were -9.91 kcal/mol whereas fenofibrate were -8.80 kcal/mol in PPAR α, in another case PPAR γ was -7.80 kcal/mol whereas rosiglitazone was -8.03 kcal/mol. </plain></SENT>
<SENT sid="43" pm="."><plain>To confirm the specificity and sensitivity of MHY 966 in the regulation of transcriptional activities of PPARs, reporter gene assay were performed. </plain></SENT>
<SENT sid="44" pm="."><plain>As shown in Figure 1C and D, MHY 966 increased PPAR α and γ in a dose dependent manner in AC2F rat liver cells. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0076820-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0076820.g001</object-id><label>Figure 1</label><caption><title><text><SENT sid="45" pm="."><plain>MHY 966 functioned as a PPAR α/γ dual agonist. </plain></SENT>
</text></title><p><text><SENT sid="46" pm="."><plain>(A) and (B), Docking simulation was performed to identify interaction between LBD and MHY 966. </plain></SENT>
<SENT sid="47" pm="."><plain>Docking modes of MHY 966 on the LBD of human PPAR α and γ. MHY 966 has similar binding sites compared with known PPAR α and γ agonist, fenofibrate and rosiglitazone, respectively. </plain></SENT>
<SENT sid="49" pm="."><plain>For luciferase assay, AC2F cells overexpressing PPAR α (C) and PPAR γ (D) were treated with 1 or 5 μM fenofibrate, rosiglitazone, or MHY 966 for 6 h. </plain></SENT>
<SENT sid="50" pm="."><plain>Bars represents means ± SEMs of triplicates results. *** P &lt; 0.001, ** P &lt; 0.01 and * P &lt; 0.05 versus cell treated with PC DNA group. </plain></SENT>
<SENT sid="51" pm="."><plain>C and D, . </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0076820.g001"/></fig></SecTag></sec><sec id="s2.2"><title><text><SENT sid="52" pm="."><plain>MHY 966 inhibited UVB-induced collagen digestion in HRM2 mice </plain></SENT>
</text></title><p><text><SENT sid="53" pm="."><plain>Histological staining with Masson-trichrome for dermal collagen fibrates showed that exposure UVB reduced cellular collagen levels in the intra dermis, indicating elevated digestion of dermal connective tissues. </plain></SENT>
<SENT sid="54" pm="."><plain>In contrast, strong staining of collagen fibers was observed in MHY 966 treated HRM2 mice exposed to UVB as compared with that observed in UVB alone exposed mice (Figure 2A). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0076820-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0076820.g002</object-id><label>Figure 2</label><caption><title><text><SENT sid="55" pm="."><plain>Effects of the topical administration of MHY 966 on UVB-induced epidermal thickness and collagen destruction in HRM2 mouse dorsal skin. </plain></SENT>
</text></title><p><text><SENT sid="56" pm="."><plain>Histological sections of mouse dorsal skins were stained with Masson-trichrome for dermal collagen fibrates (A). </plain></SENT>
<SENT sid="57" pm="."><plain>Paraffin sections were photographed after H&amp;E staining for UVB induced skin damage (B). </plain></SENT>
<SENT sid="58" pm="."><plain>Original magnification: 200 X. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0076820.g002"/></fig></SecTag><p><text><SENT sid="59" pm="."><plain>Skin epidermal thickening was measured in UVB irradiated HRM2 mice by H&amp;E staining, and epidermal thickness of dorsal skin was found to be significantly increased by UVB. </plain></SENT>
<SENT sid="60" pm="."><plain>On the other hand, the topical application of MHY 966 inhibited this UVB induced increase in epidermal thickness. </plain></SENT>
<SENT sid="61" pm="."><plain>Accordingly, topical treatment with MHY 966 was found to have protective effects on UVB induced skin damage (Figure 2B). </plain></SENT>
</text></p></sec><sec id="s2.3"><title><text><SENT sid="62" pm="."><plain>MHY 966 reduced pro-inflammatory protein expression in UVB induced HRM2 mice </plain></SENT>
</text></title><p><text><SENT sid="63" pm="."><plain>Previous studies have indicated that pro-inflammatory response is a causative factor of wrinkle formation and skin aging [14]. </plain></SENT>
<SENT sid="64" pm="."><plain>In the present study, we examined the effect of MHY 966 on the inflammatory responses to UVB in dorsal skin by activating PPAR α and PPAR γ. Western blot analysis shows that PPAR α and PPAR γ expression levels increased in MHY 966 treated mice skin (Figure 3 A). </plain></SENT>
<SENT sid="66" pm="."><plain>Indeed, while UVB treated mice showed elevated levels of NF-κB, and NF-κB mediated inflammatory factors, such as metalloprotease-1 (MMP-1), iNOS and COX-2 as compared with normal control mice, treatment with MHY 966 reduced these expressional elevations (Figure 3 B, C). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0076820-g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0076820.g003</object-id><label>Figure 3</label><caption><title><text><SENT sid="67" pm="."><plain>MHY 966 both activated PPAR α and γ, and inhibited inflammatory responses in UVB-induced HRM2 mouse skins. </plain></SENT>
</text></title><p><text><SENT sid="68" pm="."><plain>Western blot analysis was performed to detect the levels of PPAR α PPAR γ (A), NF-κB (B), MMP-1, COX-2 and iNOS (C) in skin hommogenate. </plain></SENT>
<SENT sid="69" pm="."><plain>TFⅡB and β-actin blots were shown to clarify the same amount of protein loaded in nuclear and cytosolic fraction, respectively. </plain></SENT>
<SENT sid="70" pm="."><plain>0.4 or 2 μM of MHY 966 was topically applied on dorsal skin daily at for 17 days and then exposed to UVB using a BEX-800 UVB lamp (UltraLun, Claremont, Ca, USA) at 150 mJ/cm2. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0076820.g003"/></fig></SecTag></sec><sec id="s2.4"><title><text><SENT sid="71" pm="."><plain>MHY 966 improved lipid peroxidation by inhibiting ONOO- generation </plain></SENT>
</text></title><p><text><SENT sid="72" pm="."><plain>NO is synthesized by iNOS and generates highly reactive ONOO-. </plain></SENT>
<SENT sid="73" pm="."><plain>Thus, we examined whether MHY 966 suppresses ONOO- generation. </plain></SENT>
<SENT sid="74" pm="."><plain>In accordance with previous reports, ONOO- interacted with lipid-rich plasma membranes and caused lipid peroxidation. </plain></SENT>
<SENT sid="75" pm="."><plain>Previous research indicated that UVB produces ONOO- and that this causes lipid peroxidation. </plain></SENT>
<SENT sid="76" pm="."><plain>In the present study, whereas UVB induced mice showed higher levels of ONOO- than normal control mice, treatment with MHY 966 reduced ONOO- levels (Figure 4A). </plain></SENT>
<SENT sid="77" pm="."><plain>In addition, MHY 966 effectively reduced UVB-induced increases in MDA levels. </plain></SENT>
<SENT sid="78" pm="."><plain>(Figure 4B) </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0076820-g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0076820.g004</object-id><label>Figure 4</label><caption><title><text><SENT sid="79" pm="."><plain>Effects of MHY 966 on UVB-induced ONOO- and MDA in HRM2 mouse dorsal skin. </plain></SENT>
</text></title><p><text><SENT sid="80" pm="."><plain>ONOO- was measured by DHR-123 with a fluorescent probe (A) and MDA was measured by TBARS assay (B) in HRM2 mouse dorsal skin. </plain></SENT>
<SENT sid="81" pm="."><plain>Bar represent means ± SEMs of six mice and normalized mg/protein. *** P &lt; 0.001, ** P &lt; 0.01 and * P &lt; 0.05 versus UVB-exposed mice. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0076820.g004"/></fig></SecTag></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="discussion" id="s3"><title><text><SENT sid="82" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="83" pm="."><plain>A number of authors have reported that UVB causes serious oxidative damage in skin, because the polyunsaturated fatty acids of cellular membrane are attacked by lipid peroxides [4,5]. </plain></SENT>
<SENT sid="84" pm="."><plain>Skin photoaging is characterized by the degradation of collagen which leads to enhanced wrinkle formation [15] via expression of Matrix metalloproteases (MMPs). </plain></SENT>
<SENT sid="85" pm="."><plain>MMPs are important players in UVB induced skin diseases including psoriasis and cancer, and aging. </plain></SENT>
</text></p><p><text><SENT sid="86" pm="."><plain>The present studies have showed that PPARs regulate important cellular functions, including cell proliferation, differentiation, and inflammation. </plain></SENT>
<SENT sid="87" pm="."><plain>The anti-inflammatory effects of PPARs are important because pro-inflammatory responses play key roles in UVB induced skin aging. </plain></SENT>
<SENT sid="88" pm="."><plain>In particular, PPAR signals have been demonstrated to play a role in skin development and barrier formation [16,17]. </plain></SENT>
<SENT sid="89" pm="."><plain>In the present study, we found that MHY 966 activates PPAR α and γ, but the potency was less than that of fenofibrate, a PPAR α agonist, and rosiglitazone, a PPAR γ agonist, in in vitro transcriptional activity (Figure 1). </plain></SENT>
<SENT sid="90" pm="."><plain>However, this result conflict with the conclusion in our previous study [13]. </plain></SENT>
<SENT sid="91" pm="."><plain>In our previous study, we performed the Lantha Screen TR-FRET PPAR γ competitive binding assay. </plain></SENT>
<SENT sid="92" pm="."><plain>It just shows the interaction of an agonist with the ligand binding domain of PPAR γ. In this study, however, we conducted luciferase assay in AC2F cells. </plain></SENT>
<SENT sid="94" pm="."><plain>In cell culture systems, the results may vary depending on a variety of conditions. </plain></SENT>
<SENT sid="95" pm="."><plain>Thus, the conflict of conclusion happened between the previous and present studies, because of the different types of the experiments. </plain></SENT>
</text></p><p><text><SENT sid="96" pm="."><plain>In addition, MHY 966 was found to be a more potent agonist of PPAR α than PPAR γ. Furthermore, PPAR γ agonist like rosiglitazone and pioglitazone, typically possess a small polar region and a hydrophobic region that form hydrogen bonds and hydrophobic interactions, respectively, with LBD (ligand binding domain) [18]. </plain></SENT>
<SENT sid="98" pm="."><plain>Hydrogen bonding typically occurs between His323, Tyr473, and His289 of PPAR γ LBD and carbonyl oxygens of the ligand. </plain></SENT>
<SENT sid="99" pm="."><plain>Hydrogen bonding of the ligand to Tyr473 is critical for stabilization of the AF-2 region of name [19]. </plain></SENT>
<SENT sid="100" pm="."><plain>However, MHY 966 does not form a hydrogen bond with Tyr473, which is probably why binding between PPAR γ and MHY 966 is weak compared with rosiglitazone. </plain></SENT>
</text></p><p><text><SENT sid="101" pm="."><plain>MHY 966 activates PPAR α and γ, but the potency was less than that of fenofibrate, a PPAR α agonist, and rosiglitazone, a PPAR γ agonist, in in vitro transcriptional activity. </plain></SENT>
<SENT sid="102" pm="."><plain>However, it is necessary to use MHY 966 instead of fenofibrate or rosiglitazone for their side effects [20]. </plain></SENT>
<SENT sid="103" pm="."><plain>In addition, PPAR γ related side effects can be minimized by the combination of PPAR γ potency and PPAR α potency equal to or more than the PPAR γ potency [21]. </plain></SENT>
<SENT sid="104" pm="."><plain>Furthermore, because the synthetic PPAR α and γ dual agonist independently ameliorates inflammation, the PPAR α/γ dual agonist might be even more effective. </plain></SENT>
</text></p><p><text><SENT sid="105" pm="."><plain>UVB radiation is known to damage DNA directly and indirectly and to perturb extracellular matrix homeostasis by increasing MMP activity [22]. </plain></SENT>
<SENT sid="106" pm="."><plain>Histologic and ultrastructural studies have shown that photodamaged skin is associated with increased epidermal thickness and alterations in connective tissue organization [23]. </plain></SENT>
<SENT sid="107" pm="."><plain>Furthermore, in one study, MMP activity was increased in skin exposed to UVB, and this upregulation led to collagen destruction and photoaging [24]. </plain></SENT>
<SENT sid="108" pm="."><plain>In addition, in this previous study, it was shown that UVB augmented collagen degradation in dermal fibroblasts probably via activated collagenolytic MMP. </plain></SENT>
<SENT sid="109" pm="."><plain>On the other hand, the present study shows that MHY 966 inhibits UVB-induced MMP-1 overexpression and collagen degradation by suppressing NF-κB activation (Figure 3). </plain></SENT>
<SENT sid="110" pm="."><plain>This inhibition is probably related to the effect of PPARs on NF-κB-mediated transactivation exhibits because NF-κB activity is essential for MMP-1 expression [25], and PPARs could interfere with the NF-κB pathway via reducing NF-κB binding activity [26] and physically interacting with both p65 and p50 [27]. </plain></SENT>
<SENT sid="111" pm="."><plain>Therefore, these findings support the view that MHY 966 could inhibit inflammatory response via direct or indirect interfere with NF-κB. </plain></SENT>
</text></p><p><text><SENT sid="112" pm="."><plain>UVB exposure leads to DNA damage and the formation of ROS, induces markers of inflammatory response like COX-2 and iNOS by activating NF-κB, and damages the integrity of extracellular matrix [28]. </plain></SENT>
<SENT sid="113" pm="."><plain>UVB has also been shown to upregulate iNOS expression to produce NO at high enough levels to react with superoxide to form ONOO- and initiate lipid peroxidation processes [29]. </plain></SENT>
<SENT sid="114" pm="."><plain>In fact, lipid peroxidation induced by oxidative stress is a cause of the mass of keratinocytes, the cellular membranes of which contain considerable amounts of unsaturated lipid and cholesterol. </plain></SENT>
<SENT sid="115" pm="."><plain>In a previous study, we found that MHY 966 treatment reduces NO level increases caused by UVB exposure [13]. </plain></SENT>
<SENT sid="116" pm="."><plain>On the other hand, we found MHY 966 suppressed UVB-induced inflammatory response, including COX-2 and iNOS, by inhibited not ROS generation (data not shown) but NF-κB activation (Figure 3), thus we supposed that MHY 966 attenuated the UVB-induced overexpression of ONOO- , and inhibited lipid peroxidation processes (Figure 4). </plain></SENT>
<SENT sid="117" pm="."><plain>These findings indicate MHY 966 inhibits epidermal thickening of dorsal skin by inhibiting UVB-induced inflammatory responses. </plain></SENT>
</text></p><p><text><SENT sid="118" pm="."><plain>Summarizing, we found that the novel PPAR α/γ dual agonist, MHY 966 favorably affects collagen degradation caused by skin photoaging by activating PPAR α and γ, and thus, inhibits inflammatory responses. </plain></SENT>
<SENT sid="119" pm="."><plain>Therefore, we suggest PPAR α/γ dual agonists, be considered potential agents that inhibit wrinkle formation and skin photoaging, and that MHY 966 be viewed as a potential lead compound for the development of anti-skin aging agents. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="s4"><title><text><SENT sid="120" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec id="s4.1"><title><text><SENT sid="121" pm="."><plain>Docking simulation of PPARs and target compounds </plain></SENT>
</text></title><p><text><SENT sid="122" pm="."><plain>The crystal structure of PPAR α/γ were extracted from the PDB archives (entry code PPAR α: 1K7L, PPAR γ: 3DZY) [30] and employed as the target in docking calculations. </plain></SENT>
<SENT sid="123" pm="."><plain>For docking simulation, we used AutoDock4.2 program [31] which is the most commonly used because of its automated docking capability [12] among the many tools available for in silico protein-ligand docking. </plain></SENT>
<SENT sid="124" pm="."><plain>Because AutoDock program uses a grid-based method to allow rapid evaluation of the binding energy of trial conformations, we computed a grid box of the docking pocket on PPAR α/γ using the AutoGrid4 included in the Autodock4.2 program. </plain></SENT>
<SENT sid="125" pm="."><plain>The binding pocket defined as the grid box made of 40×40×40 points with grid spacing of 0.375 Å. The binding pocket was centered on the predefined active sites in human PPAR α and γ structures which got from PDB database. </plain></SENT>
<SENT sid="127" pm="."><plain>We performed docking simulations between PPAR α/γ and MHY 966, or with a fenofibrate (a rosiglitazone), which was used as the reference inhibitor. </plain></SENT>
<SENT sid="128" pm="."><plain>To prepare compounds for docking simulation, we performed the following steps: (1) 2D structures were converted into 3D structures, (2) charges were calculated, and (3) hydrogen atoms were added using the ChemOffice program (http://www.cambridgesoft.com). </plain></SENT>
</text></p></sec><sec id="s4.2"><title><text><SENT sid="129" pm="."><plain>Shared pharmacophore of target compounds </plain></SENT>
</text></title><p><text><SENT sid="130" pm="."><plain>A pharmacophore is an ensemble of ligand features required for interaction with a specific receptor in biological response [32]. </plain></SENT>
<SENT sid="131" pm="."><plain>The pharmacophore model was generated using the LigandScout 3.0 program [33]. </plain></SENT>
<SENT sid="132" pm="."><plain>Based on atom types, the chemical features of target compounds were defined in terms of pharmacophore elements, such as, hydrogen bond acceptors, hydrogen bond donors, positive ionizable areas, negative ionizable areas, hydrophobic interactions, and aromatic rings. </plain></SENT>
</text></p></sec><sec id="s4.3"><title><text><SENT sid="133" pm="."><plain>Transfection and luciferase assay </plain></SENT>
</text></title><p><text><SENT sid="134" pm="."><plain>For luciferase assays, 0.1 ug of plasmid was transfected into 5 x 104 cells per well seeded in a 24-well plate in 500 μl of DMEM supplemented with 5% FBS at 37 °C in a humidified 95% air/5% CO2 atmosphere. </plain></SENT>
<SENT sid="135" pm="."><plain>Cells were transfected with lipofectamine transfection reagent and the plasmids used for transfection with 3xAOX-TK-luciferase reporter vector. </plain></SENT>
<SENT sid="136" pm="."><plain>After 12 h of transfection, cells were washed, and treated with MHY 966, fenofibrate, or rosiglitazone for 6 h and luciferase activities were then detected using the One-Glo Luciferase Assay System (Promega, USA). </plain></SENT>
<SENT sid="137" pm="."><plain>Luciferase activities were measured using a TECAN GENios luminescence plate reader (Tecan Instruments, Salzburg, Austria) </plain></SENT>
</text></p></sec><sec id="s4.4"><title><text><SENT sid="138" pm="."><plain>Animals and skin characteristics </plain></SENT>
</text></title><p><text><SENT sid="139" pm="."><plain>Male, 4-week old, HRM2 mice were obtained from the Hoshino Laboratory (Saitama, Japan) and maintained under a 12 h light/dark cycle at 23 ± 1°C and 50 ± 5% RH under specific pathogen-free conditions on a standard diet (Superfeed Co. </plain></SENT>
<SENT sid="140" pm="."><plain>South Korea) ad libitum. </plain></SENT>
<SENT sid="141" pm="."><plain>After acclimatization for 1 week, mice were randomly divided into 5 groups of 6 animals. </plain></SENT>
<SENT sid="142" pm="."><plain>MHY 966 was dissolved in vehicle consisting of ethanol and propylene glycol (3:7 vol/vol), and then topically applied to a designated 2 cm2 X 2 cm2 site on dorsal skin daily for 17 days. </plain></SENT>
<SENT sid="143" pm="."><plain>Mice were exposed to UVB using a BEX-800 UVB lamp (UltraLun, Claremont, Ca, USA) at 150 mJ/cm2. </plain></SENT>
<SENT sid="144" pm="."><plain>A photograph of the dorsal skin of each mouse was taken using a digital camera (Canon, Japan), just prior to sacrifice. </plain></SENT>
<SENT sid="145" pm="."><plain>The animal protocol used in this study has been reviewed by the Pusan National University-Institutional Animal Care and Use Committee (PNU-IACUC) on their ethical procedures and scientific care, and it has been approved (Approval Number PNU-2012-0102). </plain></SENT>
</text></p></sec><sec id="s4.5"><title><text><SENT sid="146" pm="."><plain>Histology and microscopy </plain></SENT>
</text></title><p><text><SENT sid="147" pm="."><plain>For histological analyses, skins were fixed in 10% formalin at room temperature. </plain></SENT>
<SENT sid="148" pm="."><plain>Paraffin-embedded skin specimens were sectioned at 5 μm, deparaffinized, and stained with Masson-trichrome to visualize collagen fibers and stained with hematoxylin and eosin (H&amp;E) for light microscopic evaluation. </plain></SENT>
<SENT sid="149" pm="."><plain>Staining tissue sections were examined under an optical microscope (Eclipse TS100; Nikon Instruments Inc., Melville, NY, USA), and five or six photographs (200 X) were taken per section. </plain></SENT>
<SENT sid="150" pm="."><plain>Epidermal thickness was defined as the distance from the basal layer to the stratum granulosum/stratum corneum junction. </plain></SENT>
<SENT sid="151" pm="."><plain>Thicknesses were measured in each photograph at 10 random sites. </plain></SENT>
</text></p></sec><sec id="s4.6"><title><text><SENT sid="152" pm="."><plain>Quantification of ONOO- and malondialdehyde (MDA) in skin homogenates </plain></SENT>
</text></title><p><text><SENT sid="153" pm="."><plain>ONOO- generation was measured by monitoring the oxidation of DHR 123. </plain></SENT>
<SENT sid="154" pm="."><plain>Briefly, 10 μl of skin homogenate was added to a rhodamine solution (50 mM sodium phosphate buffer, 90 mM sodium chloride, 5 mM diethylenetriaminepentaacetate [DTPA], and DHR 123). </plain></SENT>
<SENT sid="155" pm="."><plain>Changes in fluorescence intensity were measured every 5 min for 30 min on a fluorescence plate reader at excitation and emission wavelengths of 485 nm and 530 nm, respectively. </plain></SENT>
</text></p><p><text><SENT sid="156" pm="."><plain>To quantification of the end-products of lipid peroxidation, to be specific MDA, we performed thiobarbituric acid reactive substances (TBARS) assay in mouse skin homogenates. </plain></SENT>
<SENT sid="157" pm="."><plain>The 100 μl tissue samples were mixed in e-tubes containing 40 μl of 8.1% SDS solution, 300 μl of 20% acetic acid, and 200 μl of 1.2% thiobarbiturate solution. </plain></SENT>
<SENT sid="158" pm="."><plain>Tubes were heated in boiling water for 30 min, cooled to room temperature, 300 μl butanol was added, and mixtures were centrifuged at 1500 x g for 10 min. </plain></SENT>
<SENT sid="159" pm="."><plain>The absorbance of butanol layer was measured at 532 nm. </plain></SENT>
<SENT sid="160" pm="."><plain>Using MDA standard, TBARS were calculated as μM/mg protein. </plain></SENT>
</text></p></sec><sec id="s4.7"><title><text><SENT sid="161" pm="."><plain>Statistical analysis </plain></SENT>
</text></title><p><text><SENT sid="162" pm="."><plain>All results are expressed as means ± SEMs. </plain></SENT>
<SENT sid="163" pm="."><plain>Treatments were compared by one-way ANOVA followed by Dunnett’s test. </plain></SENT>
<SENT sid="164" pm="."><plain>Statistical significance was accepted for P values &lt; 0.05. </plain></SENT>
</text></p></sec></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="165" pm="."><plain>We thank the Aging Bank for supplying research information. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="B1"><text><SENT sid="166" pm="."><plain>1 RicoteM, LiAC, WillsonTM, KellyCJ, GlassCK (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391: 79-82. doi:10.1038/34178. </plain></SENT>
<SENT sid="167" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/9422508">9422508</ext-link>.9422508 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="168" pm="."><plain>2 ZadelaarAS, BoestenLS, JukemaJW, van VlijmenBJ, KooistraT et al. (2006) Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice. Arterioscler Thromb Vasc Biol 26: 2560-2566. doi:10.1161/01.ATV.0000242904.34700.66. </plain></SENT>
<SENT sid="169" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/16931788">16931788</ext-link>.16931788 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="170" pm="."><plain>3 AtharM (2002) Oxidative stress and experimental carcinogenesis. Indian J Exp Biol 40: 656-667. </plain></SENT>
<SENT sid="171" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/12587714">12587714</ext-link>.12587714 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="172" pm="."><plain>4 DavidsonSM, DuchenMR (2006) Calcium microdomains and oxidative stress. Cell Calcium 40: 561-574. doi:10.1016/j.ceca.2006.08.017. </plain></SENT>
<SENT sid="173" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17049598">17049598</ext-link>.17049598 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="174" pm="."><plain>5 HitoshiY, LinN, PayanDG, MarkovtsovV (2010) The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases. Int J Hematol 91: 189-200. doi:10.1007/s12185-010-0531-y. </plain></SENT>
<SENT sid="175" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/20191331">20191331</ext-link>.20191331 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="176" pm="."><plain>6 de GruijlFR, Van der LeunJC (1994) Estimate of the wavelength dependency of ultraviolet carcinogenesis in humans and its relevance to the risk assessment of a stratospheric ozone depletion. Health Phys 67: 319-325. doi:10.1097/00004032-199410000-00001. </plain></SENT>
<SENT sid="177" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/8083043">8083043</ext-link>.8083043 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="178" pm="."><plain>7 KatiyarSK, AfaqF, AzizuddinK, MukhtarH (2001) Inhibition of UVB-induced oxidative stress-mediated phosphorylation of mitogen-activated protein kinase signaling pathways in cultured human epidermal keratinocytes by green tea polyphenol (-)-epigallocatechin-3-gallate. Toxicol Appl Pharmacol 176: 110-117. doi:10.1006/taap.2001.9276. </plain></SENT>
<SENT sid="179" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/11601887">11601887</ext-link>.11601887 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="180" pm="."><plain>8 OpländerC, CorteseMM, KorthHG, KirschM, MahotkaC et al. (2007) The impact of nitrite and antioxidants on ultraviolet-A-induced cell death of human skin fibroblasts. Free Radic Biol Med 43: 818-829. doi:10.1016/j.freeradbiomed.2007.05.030. </plain></SENT>
<SENT sid="181" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17664145">17664145</ext-link>.17664145 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="182" pm="."><plain>9 SuschekCV, BrivibaK, Bruch-GerharzD, SiesH, KrönckeKD et al. (2001) Even after UVA-exposure will nitric oxide protect cells from reactive oxygen intermediate-mediated apoptosis and necrosis. Cell Death Differ 8: 515-527. doi:10.1038/sj.cdd.4400839. </plain></SENT>
<SENT sid="183" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/11423912">11423912</ext-link>.11423912 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="184" pm="."><plain>10 SuschekCV, KrischelV, Bruch-GerharzD, BerendjiD, KrutmannJ et al. (1999) Nitric oxide fully protects against UVA-induced apoptosis in tight correlation with Bcl-2 up-regulation. J Biol Chem 274: 6130-6137. doi:10.1074/jbc.274.10.6130. </plain></SENT>
<SENT sid="185" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/10037696">10037696</ext-link>.10037696 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="186" pm="."><plain>11 BeckmanJS, CrowJP (1993) Pathological implications of nitric oxide, superoxide and peroxynitrite formation. Biochem Soc Trans 21: 330-334. </plain></SENT>
<SENT sid="187" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/8395426">8395426</ext-link>.8395426 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="188" pm="."><plain>12 PryorWA, SquadritoGL (1995) The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol 268: L699-L722. </plain></SENT>
<SENT sid="189" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/7762673">7762673</ext-link>.7762673 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="190" pm="."><plain>13 ChoiYJ, UeharaY, ParkJY, ChungKW, HaYM et al. (2012) Suppression of melanogenesis by a newly synthesized compound, MHY966 via the nitric oxide/protein kinase G signaling pathway in murine skin. J Dermatol Sci 68: 164-171. doi:10.1016/j.jdermsci.2012.09.014. </plain></SENT>
<SENT sid="191" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/23088959">23088959</ext-link>.23088959 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="192" pm="."><plain>14 GiacomoniPU, ReinG (2004) A mechanistic model for the aging of human skin. Micron 35: 179-184. doi:10.1016/j.micron.2003.11.004. </plain></SENT>
<SENT sid="193" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/15036272">15036272</ext-link>.15036272 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="194" pm="."><plain>15 BissettDL, HannonDP, OrrTV (1987) An animal model of solar-aged skin: histological, physical, and visible changes in UV-irradiated hairless mouse skin. Photochem Photobiol 46: 367-378. doi:10.1111/j.1751-1097.1987.tb04783.x. </plain></SENT>
<SENT sid="195" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/3671514">3671514</ext-link>.3671514 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="196" pm="."><plain>16 HanleyK, FeingoldKR, KömüvesLG, EliasPM, MugliaLJ et al. (1998) Glucocorticoid deficiency delays stratum corneum maturation in the fetal mouse. J Invest Dermatol 111: 440-444. doi:10.1046/j.1523-1747.1998.00303.x. </plain></SENT>
<SENT sid="197" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/9740238">9740238</ext-link>.9740238 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="198" pm="."><plain>17 ThuillierP, BrashAR, KehrerJP, StimmelJB, LeesnitzerLM et al. (2002) Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors. Biochem J 366: 901-910. </plain></SENT>
<SENT sid="199" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/12069687">12069687</ext-link>.12069687 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="200" pm="."><plain>18 PochettiG, GodioC, MitroN, CarusoD, GalmozziA et al. (2007) Insights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor gamma ligand-binding domain in the complex with two enantiomeric ligands. J Biol Chem 282: 17314-17324. doi:10.1074/jbc.M702316200. </plain></SENT>
<SENT sid="201" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17403688">17403688</ext-link>.17403688 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="202" pm="."><plain>19 BruningJB, ChalmersMJ, PrasadS, BusbySA, KameneckaTM et al. (2007) Partial agonists activate PPARgamma using a helix 12 independent mechanism. Structure 15: 1258-1271. doi:10.1016/j.str.2007.07.014. </plain></SENT>
<SENT sid="203" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17937915">17937915</ext-link>.17937915 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="204" pm="."><plain>20 RubenstrunkA, HanfR, HumDW, FruchartJC, StaelsB (2007) Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 1771: 1065-1081. doi:10.1016/j.bbalip.2007.02.003. </plain></SENT>
<SENT sid="205" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17428730">17428730</ext-link>.17428730 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="206" pm="."><plain>21 SeberS, UcakS, BasatO, AltuntasY (2006) The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. Diabetes Res Clin Pract 71: 52-58. doi:10.1016/j.diabres.2005.05.009. </plain></SENT>
<SENT sid="207" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/16009445">16009445</ext-link>.16009445 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="208" pm="."><plain>22 Scharffetter-KochanekK, BrenneisenP, WenkJ, HerrmannG, MaW et al. (2000) Photoaging of the skin from phenotype to mechanisms. Exp Gerontol 35: 307-316. doi:10.1016/S0531-5565(00)00098-X. </plain></SENT>
<SENT sid="209" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/10832052">10832052</ext-link>.10832052 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="210" pm="."><plain>23 ChoHS, LeeMH, LeeJW, NoKO, ParkSK et al. (2007) Anti-wrinkling effects of the mixture of vitamin C, vitamin E, pycnogenol and evening primrose oil, and molecular mechanisms on hairless mouse skin caused by chronic ultraviolet B irradiation. Photodermatol Photoimmunol Photomed 23: 155-162. doi:10.1111/j.1600-0781.2007.00298.x. </plain></SENT>
<SENT sid="211" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17803593">17803593</ext-link>.17803593 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="212" pm="."><plain>24 BaeJY, ChoiJS, ChoiYJ, ShinSY, KangSW et al. (2008) (-)Epigallocatechin gallate hampers collagen destruction and collagenase activation in ultraviolet-B-irradiated human dermal fibroblasts: involvement of mitogen-activated protein kinase. Food Chem Toxicol 46: 1298-1307. doi:10.1016/j.fct.2007.09.112. </plain></SENT>
<SENT sid="213" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/18226437">18226437</ext-link>.18226437 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="214" pm="."><plain>25 BondM, ChaseAJ, BakerAH, NewbyAC (2001) Inhibition of transcription factor NF-kappaB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc Res 50: 556-565. doi:10.1016/S0008-6363(01)00220-6. </plain></SENT>
<SENT sid="215" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/11376631">11376631</ext-link>.11376631 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="216" pm="."><plain>26 DeleriveP, Martin-NizardF, ChinettiG, TrotteinF, FruchartJC et al. (1999) Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 85: 394-402. doi:10.1161/01.RES.85.5.394. </plain></SENT>
<SENT sid="217" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/10473669">10473669</ext-link>.10473669 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="218" pm="."><plain>27 DeleriveP, FruchartJC, StaelsB (2001) Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 169: 453-459. doi:10.1677/joe.0.1690453. </plain></SENT>
<SENT sid="219" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/11375115">11375115</ext-link>.11375115 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="220" pm="."><plain>28 NicholsJA, KatiyarSK (2010) Skin photoprotection by natural polyphenols: anti-inflammatory, antioxidant and DNA repair mechanisms. Arch Dermatol Res 302: 71-83. doi:10.1007/s00403-009-1001-3. </plain></SENT>
<SENT sid="221" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/19898857">19898857</ext-link>.19898857 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="222" pm="."><plain>29 RadiR, BeckmanJS, BushKM, FreemanBA (1991) Peroxynitrite oxidation of sulfhydryls. </plain></SENT>
<SENT sid="223" pm="."><plain>The cytotoxic potential of superoxide and nitric oxide. J Biol Chem 266: 4244-4250. </plain></SENT>
<SENT sid="224" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/1847917">1847917</ext-link>.1847917 </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="225" pm="."><plain>30 XuHE, LambertMH, MontanaVG, PlunketKD, MooreLB et al. (2001) Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 98: 13919-13924. doi:10.1073/pnas.241410198. </plain></SENT>
<SENT sid="226" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/11698662">11698662</ext-link>.11698662 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="227" pm="."><plain>31 MorrisGM, HueyR, LindstromW, SannerMF, BelewRK et al. (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 30: 2785-2791. doi:10.1002/jcc.21256. </plain></SENT>
<SENT sid="228" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/19399780">19399780</ext-link>.19399780 </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="229" pm="."><plain>32 OlesenH, GiwercmanA, De KretserDM, MortimerD, OshimaH et al. (1998) International Society of Andrology and International Union of Pure and Applied Chemistry, Clinical Chemistry Section, Commission on Nomenclature, and International Federation of Clinical Chemistry Scientific Division. </plain></SENT>
<SENT sid="230" pm="."><plain>Properties and units in the clinical laboratory sciences XIII. </plain></SENT>
<SENT sid="231" pm="."><plain>Properties and units in reproduction and fertility (IUPAC-IFCC technical Report 1998). Clin Chim Acta 271: S5-26  </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="232" pm="."><plain>33 WolberG, LangerT (2005) LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model 45: 160-169. doi:10.1021/ci049885e. </plain></SENT>
<SENT sid="233" pm="."><plain>PubMed: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/15667141">15667141</ext-link>.15667141 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
